Arrhythmia Research Technology, Inc. Declares Cash Dividend.FITCHBURG, Mass. -- Arrhythmia Research Technology, Inc. (the "Company") (AMEX AMEX See: American Stock Exchange : HRT HRT abbr. hormone replacement therapy Hormone replacement therapy (HRT) Also called estrogen replacement therapy, this controversial treatment is used to relieve the discomforts of menopause. ) announced that its Board of Directors approved the payment of a dividend of $0.06 per share to holders of record on September 13, 2005, payable on September 23, 2005. Future dividend declarations by the Board of Directors will depend upon a number of factors, including future operating results, and other investment and acquisition opportunities. James E. Rouse, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , stated "The Board of Directors of the Company declared a $0.06 cash dividend will be paid to our shareholders as a result of the earnings achieved in the first six months of 2005." About the Company: In addition to its proprietary SAECG SAECG Signal-Averaged Electrocardiogram software used in the detection of potentially lethal heart arrhythmias the Company, through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , Micron Products Inc., manufacturers silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG ECG electrocardiogram. ECG abbr. 1. electrocardiogram 2. electrocardiograph ECG Also called an electrocardiogram, it records the electrical activity of the heart. , EEG EEG: see electroencephalography. , EMS, and TENS electrodes. Micron's New England Molders division manufactures custom injection molded products for medical, electronic, industrial and consumer applications. Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks, and changing economic conditions in developing countries. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2004. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion